• Latest
Hepatitis B vaccine in a pre-filled syringe illustrating Guinea-Bissau's halted US-funded newborn vaccination trial

Guinea-Bissau halts US baby vaccine trial

3 weeks ago
Ghanaian journalist and political commentator Kwesi Pratt Jnr gestures during a discussion on Metro TV's Good Morning Ghana programme about the government's proposed New Economy and 2027 Budget

Kwesi Pratt questions Ghana’s ‘New Economy’

3 hours ago
DR Congo President Félix Tshisekedi pictured during an official visit to Washington in February 2026

DR Congo referendum law stirs third-term fears

7 hours ago
Burundi President Evariste Ndayishimiye during an official visit to the European Commission

11 Burundi opposition parties back president

7 hours ago
Ghanaian woman trader seated beside colourful textiles at Makola Market in Accra

Ghana women’s bank nears licensing decision

7 hours ago
Container vessels at a Tanzanian port, illustrating the maritime transport links needed to expand Africa–Caribbean trade

Africa–Caribbean ties need more than history

7 hours ago
General store in Eswatini's Piggs Peak region, illustrating the small retail sector affected by citizen ownership rules

Eswatini foreign shop closures raise jobs fears

7 hours ago
IAEA Director General Rafael Grossi meets Zambian parliamentarians at the agency's headquarters in Vienna in May 2025

Zambia advances nuclear plans after IAEA review

7 hours ago
Ghana's offshore Jubilee oil field, illustrating petroleum production in the country's western waters

Ghana confirms new offshore gas discovery

7 hours ago
Former Ghana Black Stars coach Chris Hughton speaks at an Africa Cup of Nations press conference

Hughton warns Ghana over coaching turmoil

1 day ago
Jean Leonard Teganya, wearing a grey sweatshirt and handcuffs, is escorted by two uniformed Rwandan security officers beside a police vehicle

US deports Rwanda genocide suspect

1 day ago
A view of the vast Jwaneng open-pit diamond mine in Botswana, operated by Debswana, the joint venture between De Beers and the Botswana government

Botswana targets 30 percent De Beers stake

1 day ago
Geotechnical survey team and equipment beside a river at Gabon’s Mabounié niobium and rare earth deposit

Gabon advances $2bn Mabounié niobium plan

1 day ago
  • About Us
  • Advertise
  • Media Kit
  • Policies and Terms
Wednesday, November 11, 2026
  • Login
  • Register
Africa Briefing
Data & Research Solutions
No Result
View All Result
  • Home
  • Business & Economy
  • News
  • Energy
  • Politics
    • Africa Abroad
  • Technology
  • Magazine
Subscribe for More
Africa Briefing
No Result
View All Result
Home Development

Guinea-Bissau halts US baby vaccine trial

Guinea-Bissau has blocked a controversial US-funded hepatitis B vaccine trial involving 14,000 newborns, after police seized vaccines from a research facility and the WHO questioned the study's ethics, reports Brendan Odoi

by Editorial Staff
3 weeks ago
in Development
Reading Time: 4 mins read
0 0
A A
0
Hepatitis B vaccine in a pre-filled syringe illustrating Guinea-Bissau's halted US-funded newborn vaccination trial

Guinea-Bissau has halted a controversial US-funded hepatitis B vaccine trial involving 14,000 newborns after police seized vaccine supplies from a research facility in Bissau. The WHO had raised serious ethical concerns about the proposed study. Illustrative image. Photo: Whispyhistory / Wikimedia Commons / CC BY-SA 4.0

0
SHARES
45
VIEWS
Share on FacebookShare on XShare on WhatsApp

Keypoints:

  • Guinea-Bissau blocks controversial newborn trial
  • Police seize vaccines from research facility
  • WHO warns of serious ethical risks

GUINEA-BISSAU has halted a controversial US-backed vaccine trial involving thousands of newborn babies, with the researchers acknowledging that the study will not proceed after authorities seized hepatitis B vaccines from a research facility in the West African country.

The decision brings a turbulent chapter in the country’s public-health research to an abrupt end. What began as a proposed scientific investigation into childhood vaccination has become an international controversy over medical ethics, government authority and the risks of conducting research among vulnerable populations.

Police seize vaccines in Bissau

The country’s judicial police raided the Bandim Health Project in the capital, Bissau, on October 19, confiscating a consignment of hepatitis B vaccines intended for children.

According to the Guinea-Bissau News Agency’s account of the operation, investigators are examining the circumstances surrounding the vaccines and whether any laws were broken.

Police were careful to stress that the seizure was part of an investigation, not evidence that the vaccines themselves were dangerous or ineffective.

The distinction is important. At the centre of the controversy is not the safety of hepatitis B vaccination, which has been established through decades of use, but whether the proposed research was scientifically justified and ethically acceptable.

Researchers confirm trial will not proceed

The clearest indication of the project’s fate came on October 21.

Frederik Schaltz-Buchholzer, one of the Danish researchers leading the study, acknowledged that the trial could no longer proceed because the necessary government approval had not been secured.

As UK’s  The Guardian newspaper reported on Wednesday, his statement followed repeated objections from Guinea-Bissau’s health authorities.

Health Minister Quinhin Nantote had already rejected suggestions that the government had authorised the controversial project.

The researchers had previously maintained that they possessed approval from a national ethics committee, but that position did not resolve the government’s objections.

The dispute exposed an important question: who ultimately has the authority to approve sensitive medical research involving children, particularly when the project is backed by foreign institutions?

Why the WHO opposed the study

The proposed trial would have enrolled approximately 14,000 newborns, randomly dividing them into two groups.

Half would receive a hepatitis B vaccine shortly after birth. The others would follow Guinea-Bissau’s existing immunisation schedule, receiving their first hepatitis B doses several weeks later.

The researchers argued that this arrangement would not deprive children of vaccinations currently available under national policy.

But the World Health Organisation (WHO) strongly disagreed with the ethical basis of the experiment.

In its official assessment of the proposed Guinea-Bissau trial, the WHO warned that withholding an already proven intervention from some participants could expose newborns to preventable harm.

The agency says vaccination at birth prevents between 70 and 95 percent of hepatitis B transmission from mother to child.

Those figures carry particular weight in Guinea-Bissau, where more than 12 percent of adults are estimated to have chronic hepatitis B.

Around two percent of children under five are also believed to be infected.

For babies who contract the virus during childbirth, the consequences can last a lifetime. Chronic hepatitis B increases the risk of serious liver disease, including cirrhosis and cancer.

US funding puts research under scrutiny

The project was due to receive $1.6m from the US Centers for Disease Control and Prevention, alongside another $1.6m from private backers.

Researchers associated with the University of Southern Denmark wanted to investigate whether administering hepatitis B vaccination alongside other childhood vaccines could have broader effects on infant health.

They have insisted that the study was not designed to challenge the vaccine’s established effectiveness against hepatitis B.

In their formal response to the WHO’s criticism, the research team argued that every participating child would receive the vaccines required under Guinea-Bissau’s existing schedule.

They also said the trial could help inform vaccination policies in other African countries.

Critics were unconvinced.

Their concern was that babies could be denied an internationally recommended birth dose simply to answer a research question whose scientific justification remained disputed.

The controversy also attracted attention because US Health Secretary Robert F Kennedy Jr has publicly supported the Danish researchers, whose work on vaccines has faced scrutiny from other scientists.

African oversight comes into focus

Beyond the scientific disagreement, the episode has highlighted the importance of African governments retaining meaningful control over research conducted within their borders.

Guinea-Bissau has a long history of collaboration with international health researchers. Such partnerships have contributed to scientific knowledge and can bring resources to health systems operating under considerable financial pressure.

But cooperation also depends on trust.

When research involves newborn babies, that trust must extend to parents, medical professionals and the national institutions responsible for protecting participants.

A June analysis in The Lancet Global Health examined the trial’s ethical shortcomings, including concerns about maternal screening, scientific methodology and research oversight.

Its findings reinforced the need for international research partnerships to meet rigorous ethical standards, particularly where poverty and limited healthcare access could influence participation.

Protecting newborns remains the priority

With the trial halted, attention now turns to what happens to the confiscated vaccines and whether Guinea-Bissau can accelerate protection against hepatitis B.

The government has already committed to introducing routine hepatitis B vaccination at birth, with nationwide implementation planned by 2028.

Health experts argue that bringing forward access to the vaccine would offer a more immediate benefit to children than pursuing the disputed experiment.

The WHO continues to recommend administering the first dose within 24 hours of birth, followed by further doses under national immunisation schedules.

The unanswered question is whether the funding and vaccines intended for the abandoned trial can now help expand access to that protection.

For Guinea-Bissau, the controversy has demonstrated that international research partnerships cannot succeed on scientific ambition alone.

They require public confidence, credible oversight and the consent of the authorities responsible for protecting participants.

And for the thousands of babies whose health was at the centre of this dispute, the most pressing issue is no longer whether the experiment should proceed, but how quickly they can receive protection against a disease that is already preventable.

 

Tags: Bandim Health ProjectGuinea-Bissauhepatitis B vaccinemedical ethicsUS-funded trialWHO
ShareTweetSend
Editorial Staff

Editorial Staff

Related Posts

Aerial view of Luanda, Angola, showing the waterfront, high-rise buildings and densely developed neighbourhoods along the bay

Luanda to overtake Lagos by 2050: World Bank

by Editorial Staff
November 3, 2026
0

Keypoints: Luanda’s population projected to reach 20.3 million by 2050 Lagos forecast to grow to 16.2 million under World Bank...

A healthcare worker prepares a lenacapavir injection for a patient at a clinic in Eswatini

$40 HIV injection moves closer to Africa

by Editorial Staff
November 3, 2026
0

Keypoints: FDA clears first generic version of twice-yearly HIV prevention injection Injections will cost $40 annually, with an initial oral...

Siemens Biograph PET-CT scanner installed in a modern diagnostic imaging suite, providing advanced medical imaging technology for cancer diagnosis and treatment planning

EASE adds $9.5m for African expansion

by Editorial Staff
October 29, 2026
0

Keypoints: New investment adds $9.5m to EASE Total equity funding reaches $24m South Africa and Ghana drive expansion EASE, the...

Older patient lying in a hospital bed at Iganga Hospital in Uganda

Older Africans face widening healthcare gaps

by Editorial Staff
October 21, 2026
0

Keypoints: Africa's older population could triple by 2050 Only 10 WHO African Region countries reported adequate programme funding in 2023...

  • Trending
  • Comments
  • Latest
Kente: Ghana’s timeless fabric of pride

Kente: Ghana’s timeless fabric of pride

1
Hilton Worldwide announces first hotel opening in Chad

Hilton Worldwide announces first hotel opening in Chad

0
Vodafone reveals strong growth in M-Pesa transactions as it launches service in Ghana

Vodafone reveals strong growth in M-Pesa transactions as it launches service in Ghana

0
Ghanaian journalist and political commentator Kwesi Pratt Jnr gestures during a discussion on Metro TV's Good Morning Ghana programme about the government's proposed New Economy and 2027 Budget

Kwesi Pratt questions Ghana’s ‘New Economy’

November 11, 2026
DR Congo President Félix Tshisekedi pictured during an official visit to Washington in February 2026

DR Congo referendum law stirs third-term fears

November 11, 2026
Burundi President Evariste Ndayishimiye during an official visit to the European Commission

11 Burundi opposition parties back president

November 11, 2026
Africa Briefing

© 2025 Africa Briefing

Quick Links

  • Home
  • About Us
  • Advertise
  • Policies and Terms

Stay Connected

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Home
  • Business & Economy
  • Energy
  • Magazine
  • News
  • Politics
    • Africa Abroad
  • Technology
  • Advertise
  • Media Kit

© 2025 Africa Briefing

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.

Discover more from Africa Briefing

Subscribe now to keep reading and get access to the full archive.

Continue reading

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
-
00:00
00:00

Queue

Update Required Flash plugin
-
00:00
00:00